Actively Recruiting
Effects of L-ARGinine and Liposomal Vitamin C Supplementation On Physical Performance
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-03-07
100
Participants Needed
1
Research Sites
84 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In older age, reduced mobility is associated with an increased risk of reduced quality of life, disability, institutionalisation, and death, as well as increased healthcare expenditures. Sarcopenia is a condition characterised by a reduction in muscle mass and strength and/or function. It is associated with several adverse outcomes, such as falls, increased risk of infection, disability, institutionalisation, and death. Currently, no pharmacological treatments are available to combat sarcopenia. The management of sarcopenia relies on the adoption of an active lifestyle, comprising resistance exercise, which may be supported by an adequate intake of protein with the diet. Recently, treatment with L-arginine and liposomal vitamin C has been shown to significantly reduce fatigue, and improve physical performance and endothelial reactivity in adult patients with Long COVID. Long COVID may be considered a model of accelerated ageing, as it recapitulates several age-associated biological processes, including chronic inflammation, oxidative stress, endothelial dysfunction and malnutrition.
CONDITIONS
Official Title
Effects of L-ARGinine and Liposomal Vitamin C Supplementation On Physical Performance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Probable sarcopenia defined according to EWGSOP2 criteria
You will not qualify if you...
- Inability or unwillingness to provide informed consent
- Nursing home residents
- Diagnosis of schizophrenia, bipolar syndrome, or other psychotic disorders
- Consumption of more than 14 alcoholic beverages per week
- Reduced cognitive performance (Mini-Mental State Examination score <26)
- Severe arthrosis
- Malignancies requiring treatment in the previous 3 years
- Lung disease requiring chronic corticosteroid or oxygen therapy
- Severe cardiovascular disease
- Parkinson's disease or other developmental neurological disorders
- Renal failure undergoing dialysis
- Chest pain, severe shortness of breath, or conditions posing safety concerns for physical tests
- Other medical, psychiatric, or behavioral factors that may interfere with study participation
- Illnesses with estimated life expectancy less than 12 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Italy, 00168
Actively Recruiting
Research Team
M
Matteo Tosato
CONTACT
G
Giordana Gava
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here